000 01188 a2200349 4500
005 20250518043513.0
264 0 _c20200428
008 202004s 0 0 eng d
022 _a2531-0437
024 7 _a10.1016/j.pulmoe.2019.04.005
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aEstevinho, F
245 0 0 _aTreatment of advanced EGFR-mutant NSCLC patients: Sequencing matters.
_h[electronic resource]
260 _bPulmonology
_c
300 _a306-309 p.
_bdigital
500 _aPublication Type: Letter
650 0 4 _aAntineoplastic Agents
_xtherapeutic use
650 0 4 _aCarcinoma, Non-Small-Cell Lung
_xdrug therapy
650 0 4 _aClinical Trials, Phase III as Topic
650 0 4 _aDNA Mutational Analysis
650 0 4 _aErbB Receptors
_xgenetics
650 0 4 _aHumans
650 0 4 _aLung Neoplasms
_xdrug therapy
650 0 4 _aMutation
650 0 4 _aProtein Kinase Inhibitors
_xtherapeutic use
700 1 _aFelizardo, M
700 1 _aFernandes, G
700 1 _aFigueiredo, A
700 1 _aLopes, J A
773 0 _tPulmonology
_gvol. 25
_gno. 5
_gp. 306-309
856 4 0 _uhttps://doi.org/10.1016/j.pulmoe.2019.04.005
_zAvailable from publisher's website
999 _c29782085
_d29782085